Activists demand more cost cuts

These two medical industry leaders are facing demands from activists to expand their current cost-cutting plans. While that pressure helps draw investor attention to their high-quality assets, Pfizer is your better choice for long-term gains.
PFIZER INC. $30 is a buy. The company (New York symbol PFE; Manufacturing… Read More

Medical spinoffs down but not out

These three medical products makers (including Kenvue, see box) have struggled as independent firms. While all three have solid prospects, embecta is the only one we see as a buy right now.
EMBECTA CORP. $16 is a spinoff buy. The company (Nasdaq symbol EMBC; Manufacturing & Industry sector;… Read More

Tap into key trends with these healthcare ETFs

The underlying growth trends for healthcare remain strong as the global population grows older and emerging economies become wealthier.
Meanwhile, new technologies and artificial intelligence (AI) will serve to boost the already-strong prospects of healthcare stocks by improving the management of patient diagnostics, administrative processes, and… Read More

ICON is Ireland’s global leader in medical research

ICON plc is a contract research organization (CRO) that provides support services to the medical manufacturing industry.
ICON provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical device firms. It is one of a few CROs with the global infrastructure to carry out… Read More